• Disulfiram at the Crossroads of Cancer and Inflammasome R...

  2025-10-19

  Disulfiram, long recognized as an anti-alcoholism drug and dopamine β-hydroxylase inhibitor, is now at the forefront of cancer and inflammasome research. This thought-leadership article synthesizes mechanistic innovation, translational guidance, and competitive positioning, guiding researchers in leveraging Disulfiram’s unique proteasome and pyroptosis-modulating properties. By integrating breakthrough findings—such as covalent cysteine targeting in inflammasome pathways—and offering actionable experimental and strategic perspectives, this piece pushes beyond traditional product narratives to articulate Disulfiram’s transformative potential for advanced biomedical discovery.

• Clasto-Lactacystin β-lactone: Accelerating Translational ...

  2025-10-18

  This thought-leadership article explores the strategic deployment of Clasto-Lactacystin β-lactone, a potent, irreversible, and cell-permeable proteasome inhibitor, as a catalyst for translational breakthroughs in ubiquitin-proteasome pathway research. By integrating mechanistic insights, recent immunology findings, competitive landscape analysis, and actionable guidance, we highlight how this precision tool empowers researchers to decode complex cellular processes, model disease, and envision therapeutic innovation beyond conventional paradigms.

407 records 28/28 page Previous First page 上5页 262728